RxDoctor Payments Data

Renika McLeod-Labissiere, MD

Family Medicine · Prospect, CTNPI 1578648606

Payments from drug & device makers

$1,566in general payments, 2019–2025

Across 93 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$244
  • GSK$173
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$147
  • Pfizer$135
  • Sanofi-aventis U.S. LLC$128
  • Takeda Pharmaceuticals U.S.A., Inc.$118
  • plus $622 from 11 others

What the payments were for

  • Food & beverage$1,562100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,566 in reported general payments places this provider in the 75th percentile of 588 family medicine providers in Connecticut.

See all family medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$46,157
Medicare patients
114
Services billed
1,974

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$50,802
JardianceEmpagliflozin37$33,158
EliquisApixaban34$27,482
JanuviaSitagliptin Phosphate15$23,637
MounjaroTirzepatide12$12,472
XareltoRivaroxaban13$9,447
Atorvastatin Calcium273$1,757
Levothyroxine Sodium149$1,513
SynthroidLevothyroxine Sodium13$1,439
Albuterol Sulfate HfaAlbuterol Sulfate42$1,058
Rosuvastatin Calcium120$1,050
Losartan Potassium80$554
Omeprazole70$480
Oxybutynin Chloride ErOxybutynin Chloride27$451
Metformin Hcl94$433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$103$50,80235 claims
Boehringer IngelheimJardiance$244$33,15837 claims
PfizerEliquis$135$27,48234 claims
MerckJanuvia$64$23,63715 claims
Lilly USA, LLCMounjaro$90$12,47212 claims
Johnson & JohnsonXarelto$25$9,44713 claims
AbbVieSynthroid$87$1,43913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 588 family medicine providers in Connecticut.

Other family medicine in Prospect

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →